CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 11, 2006--CombinatoRx, Incorporated (NASDAQ: CRXX - News), today reported financial results for the first quarter ended March 31, 2006. “CombinatoRx has made significant progress in advancing its clinical pipeline during the first part of this year, including encouraging Phase 2 data for two of our synergistic combination drug candidates; CRx-102 in hand osteoarthritis and CRx-170 in asthma,” commented Alexis Borisy, President and CEO of CombinatoRx. “In addition to our clinical accomplishments, we had marked success in a number of other key areas this quarter; including entering into collaborations that continue to mobilize our technology into new disease areas such as obesity and ophthalmic disease and raising additional capital through a private offering. We look forward to reporting data on a number of other Phase 2 clinical programs during the year.”
